To raise awareness and drive change everywhere around the world for all people living with dysimmune and inflammatory neuropathies, their families and carers.
Immune-mediated neuropathies are rare diseases that are still poorly understood, although they are potentially treatable.
To find new treatments, research is essential.
Some treatments, already known and very useful to maintain the physical autonomy of the patients, suffer from shortages almost everywhere in the world. Sometimes they are not accessible to patients at all.
Hands are a very strong symbol in dysimmune and inflammatory neuropathies as they are often affected by the disease.They are also a symbol of touch and an extension of the expression of feelings.Why not take a photo to show your support for the global DIN community during this World DIN Day?
Catherine Hall is a physician at the University of Otago in New Zealand. She has conducted historical research into the death of Alexander the Great. You will discover that the date of June 11, now dedicated to DIN DAY, was not chosen by chance…
Dr Teresinha Evangelista is a neurologist. She coordinates the European reference network EURO-NMD (neuromuscular disorders). She explains what ERNs are and discusses the integration of inflammatory dysfunctional neuropathies within the network.
Immune Globulin Therapies, historical development and futur perspectives. A subject that is often known only to experts and yet is of real interest to people with DIN. Dr Patrick Robert from the Marketing Research Bureau, has a huge expertise is the domain of global plasma derive medicinal products.
From Neuromuscular and Neuroimmunology Service, Milan University, Humanitas Research Institute, Rozzano, Milan, Italy Pr Eduardo Nobile-Orazio presents the DIN and sheds light on the subject with Italian examples.
Dr Luis Querol is neurologist at Neuromuscular BCN Hospital de la Santa Creu I Sant Pau de Barcelona. He reviews different aspects of DIN. GBS, CIDP, Nodopathies ; MMN ; MGUS-Anti-MAG, Monitoring (wearable monitoring system, biomarkers), Therapy, Clinical trials (CTs) and ongoing CTs.
